Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/6785
Title: | Growth hormone/insulin-like growth factor axis in patients with subclinical thyroid dysfunction | Authors: | Akın, Fulya. Yaylalı, Güzin Fidan. Turgut, Sebahat. Kaptanoğlu, Bünyamin. |
Keywords: | GH/IGF-I axis IGFBP-3 Subclinical hyperthyroidism Subclinical hypothyroidism growth hormone insulin levothyroxine liothyronine propranolol propylthiouracil somatomedin binding protein 3 somatomedin C thyroid hormone thyrotropin adult age distribution article controlled study euthyroidism female growth hormone blood level human hyperthyroidism hypothyroidism insulin blood level liothyronine blood level major clinical study male priority journal thyroid disease thyroid function test thyroid hormone blood level thyrotropin blood level Adult Biological Markers Female Human Growth Hormone Humans Hyperthyroidism Hypothyroidism Insulin Insulin-Like Growth Factor Binding Proteins Insulin-Like Growth Factor I Male Thyrotropin Thyroxine |
Abstract: | Objective: Our aim was to evaluate serum concentrations of GH, IGF-I, and insulin-like growth factor-binding protein-3 (IGFBP-3) in patients with subclinical thyroid dysfunction before and after normalization of thyroid function. Design and methods: The study included 51 patients (mean age 42.2 ± 1.8 years) with subclinical hypothyroidism and 30 patients (mean age 44.3 ± 2.4 years) with subclinical hyperthyroidism. A group of 37 euthyroid healthy subjects were studied as controls. Serum concentrations of TSH, FT4, FT3, GH, insulin, IGF-I, and IGFBP-3 were measured in all patients before starting therapy and after normalization of thyroid function. The dosage of levothyroxine (LT4) and antithyroid drugs was adjusted in attempt to keep the serum-free thyroxine (FT4) and thyrotropin (TSH) concentrations within the normal range. Main outcome: Baseline growth hormone levels were similar with hypothyroid group and hyperthyroid group in relation to euthyroid control subjects. Fasting serum IGF-I levels were significantly lower in the subclinical hypothyroid group compared with the control group. On the other hand, IGF-I levels of subclinical hyperthyroid patients and control group were similar. After normalization of thyroid function tests, IGF-I concentrations were increased in subclinical hypothyroid subjects, but unchanged in subclinical hyperthyroid subjects. Patients with subclinical hyperthyroidism showed slightly lower mean serum IGFBP-3 concentrations than those found in control group, but the difference was not statistically significant. Serum GH and IGFBP-3 levels were unaltered by treatment. Conclusions: In this study, it was shown that GH-IGF axis was not affected in patients with subclinical hyperthyroidism, while it was affected in patients with subclinical hypothyroidism. That is, investigation of the axis in subclinical hyperthyroidism would not bring any extra advantages, but LT4 replacement therapy could prevent abnormalities related to GH-IGF axis in patients with subclinical hypothyroidism. © 2008 Elsevier Ltd. All rights reserved. | URI: | https://hdl.handle.net/11499/6785 https://doi.org/10.1016/j.ghir.2008.11.003 |
ISSN: | 1096-6374 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Show full item record
CORE Recommender
SCOPUSTM
Citations
23
checked on Dec 14, 2024
WEB OF SCIENCETM
Citations
20
checked on Dec 20, 2024
Page view(s)
52
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.